Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G

Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.